Mucosal immunization with recombinant adenoviral vectors expressing murine gammaherpesvirus-68 genes M2 and M3 can reduce latent viral load (Q56798206)

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.104

Spectrum of Kaposi's sarcoma-associated herpesvirus, or human herpesvirus 8, diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.104

Dissecting the host response to a gamma-herpesvirus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.104

Pathogenesis of an infectious mononucleosis-like disease induced by a murine gamma-herpesvirus: role for a viral superantigen?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.104

Early establishment of gamma-herpesvirus latency: implications for immune control

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.104

Epitope-specific evolution of human CD8(+) T cell responses from primary to persistent phases of Epstein-Barr virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.104

A gammaherpesvirus-secreted activator of Vbeta4+ CD8+ T cells regulates chronic infection and immunopathology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.104

Latent murine gamma-herpesvirus infection is established in activated B cells, dendritic cells, and macrophages

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.104

Lung epithelial cells are a major site of murine gammaherpesvirus persistence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.104

Vaccination against murine gamma-herpesvirus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.104

Latent antigen vaccination in a model gammaherpesvirus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.104

T-cell responses to the M3 immune evasion protein of murid gammaherpesvirus 68 are partially protective and induced with lytic antigen kinetics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.104

Vaccine potential of a murine gammaherpesvirus-68 mutant deficient for ORF73.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.104

Effective vaccination against long-term gammaherpesvirus latency

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.104

A gamma-herpesvirus deficient in replication establishes chronic infection in vivo and is impervious to restriction by adaptive immune cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.104

Memory generation and maintenance of CD8+ T cell function during viral persistence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.104

Recombinant adenovirus vector vaccine induces stronger cytotoxic T-cell responses than recombinant vaccinia virus vector, plasmid DNA, or a combination of these

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.104

Adenoviral vectors for mucosal vaccination against infectious diseases.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.104

Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.104

MHC Class II-Associated Invariant Chain Linkage of Antigen Dramatically Improves Cell-Mediated Immunity Induced by Adenovirus Vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.104

Progressive loss of CD8+ T cell-mediated control of a gamma-herpesvirus in the absence of CD4+ T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.104

Use of recombinant adenovirus for metabolic engineering of mammalian cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.104

Deficient CD4+ T cell priming and regression of CD8+ T cell functionality in virus-infected mice lacking a normal B cell compartment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.104

Superior control of HIV-1 replication by CD8+ T cells is reflected by their avidity, polyfunctionality, and clonal turnover

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.104

High numbers of IL-2-producing CD8+ T cells during viral infection: correlation with stable memory development.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.104

Restoring function in exhausted CD8 T cells during chronic viral infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.104

Polyfunctional T cell responses are a hallmark of HIV-2 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.104

T-cell quality in memory and protection: implications for vaccine design

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.104

Epstein-Barr virus: the impact of scientific advances on clinical practice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.104

Human herpesvirus 8: biology and role in the pathogenesis of Kaposi's sarcoma and other AIDS-related malignancies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.104

Use of recombinant virus-vectored tuberculosis vaccines for respiratory mucosal immunization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.104

Incomplete effector/memory differentiation of antigen-primed CD8+ T cells in gene gun DNA-vaccinated mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.104

HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.104

Memory CD8 T-cell differentiation during viral infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.104

CD8 T cell dysfunction during chronic viral infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.104

Different functional capacities of latent and lytic antigen-specific CD8 T cells in murine gammaherpesvirus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.104

K3-mediated evasion of CD8(+) T cells aids amplification of a latent gamma-herpesvirus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.104

Inhibition of interferon-mediated antiviral activity by murine gammaherpesvirus 68 latency-associated M2 protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.104

Disruption of CCL21-induced chemotaxis in vitro and in vivo by M3, a chemokine-binding protein encoded by murine gammaherpesvirus 68.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.104

The murine gammaherpesvirus-68 gp150 acts as an immunogenic decoy to limit virion neutralization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.104

Factors controlling levels of CD8+ T-cell lymphocytosis associated with murine gamma-herpesvirus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.104

Rapid turnover of T cells in acute infectious mononucleosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.104

A secreted chemokine binding protein encoded by murine gammaherpesvirus-68 is necessary for the establishment of a normal latent load

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.104

Intramuscular rather than oral administration of replication-defective adenoviral vaccine vector induces specific CD8+ T cell responses in the gut.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.104

Identification of a gammaherpesvirus selective chemokine binding protein that inhibits chemokine action

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.104

Establishment and maintenance of gammaherpesvirus latency are independent of infective dose and route of infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.104

Three distinct regions of the murine gammaherpesvirus 68 genome are transcriptionally active in latently infected mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.104